Future Science Group

A PUBLISHER'S VIEW ON RWE STUDIES AND ARTICLES

JOANNE WALKER
HEAD OF PUBLISHING SOLUTIONS

7TH EMWA SYMPOSIUM
9 MAY 2019
REAL-WORLD EVIDENCE: A CENTRAL ROLE FOR MEDICAL COMMUNICATORS

About FSG



Future Medicine

newlands press

FUTURE SCIENCE

PharmaPlatforms

Publish Enrich Reach Engage

A platform for informed decisions on which treatment, for whom and when

MEDLINE -indexed

Impact Factor: 1.906

~6,000 views/month

~75% acceptance rate

The Evidence Base™

www.evidencebaseonline.com

Consider your audience = journal choice?



Consider your research = methodology publication?



Future ONCOLOGY

RESEARCH ARTICLE

For reprint orders, please contact: reprints@futuremedicine.com

Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research

David F Penson*[1], Daniel W Lin[2], Lawrence Karsh[3], David I Quinn[4], Daniel H Shevrin[5], Neal Shore[6], James T Symanowski[7], Bruce Brown[8], David Forer[9], Elaine K Wong[9] & Scott C Flanders[8]

Aim: This study seeks to improve the understanding of treatment patterns and associated health-related quality of life (HRQoL), clinical outcomes and healthcare utilization in US patients with castration-resistant prostate cancer (CRPC). **Patients & methods:** Treatment Registry for Outcomes in CRPC Patients (TRUMPET) is a US-based, prospective, observational multicenter registry (NCT02380274) involving patients with CRPC and their caregivers



Future ONCOLOGY

Clinical Trial Protocol

For reprint orders, please contact: reprints@futuremedicine.com

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Caitlin Costello*[,1], Faith E Davies[2], Gordon Cook[3], Jorge Vela-Ojeda[4], Jim Omel[5], Robert M Rifkin[6], Jesus Berdeja[7], Noemi Puig[8], Saad Z Usmani[9], Katja Weisel[10,11], Jeffrey A Zonder[12], Evangelos Terpos[13], Andrew Spencer[14], Xavier Leleu[15], Mario Boccadoro[16], Michael A Thompson[17], Dorothy Romanus[18], Dawn Marie Stull[19] & Vania Hungria[20]

[1]Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA
[2]Myeloma Institute, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, 72205, USA
[3]Department of Haematology, Leeds Cancer Centre, St James's University Hospital, Leeds, UK
[4]Hematology Department, La Raza Medical Center, IMSS, México City, México
[5]The Central Nebraska Myeloma Support Group, Grand Island, NE, 68801, USA
[6]Department of Hematology Research, US Oncology Research/Rocky Mountain Cancer Centers, Denver, CO, 80218, USA
[7]Department of Hematology, Sarah Cannon Research Institute, Nashville, TN, 37203, USA
[8]Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
[9]Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC, 28204, USA



Methodology

For reprint orders, please contact: reprints@futuremedicine.com

PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies

Journal of Comparative Effectiveness Research

Jamie Garside*[,1], Nollaig Healy[2], Hervé Besson[3], Ruben Hermans[4], Finlay MacDougall[4], Damien Lestelle[4], Joris Diels[3] & Wafae Iraqi[5]

[1]Janssen EMEA HEMAR, High Wycombe, UK
[2]Janssen-Cilag EMEA Medical Affairs, Dublin, Ireland
[3]Janssen EU HEMAR Statistics & Modelling, Beerse, Belgium
[4]QuintilesIMS RWE Solutions, London, UK
[5]Janssen Pharmaceuticals, Paris, France
* Author for correspondence: Tel.: +44 (0) 149 465 8410; Fax: +44 (0) 782 528 0450; jgarside@ITS.JNJ.com

Aim: PHEDRA (Platform for Haematology in EMEA: Data for Real World Analysis) is a unique, noninterventional project based on secondary data collection from real-world (RW) patient-level (health record)



Clinical Epidemiology

Dovepress

open access to scientific and medical research

Open Access Full Text Article

METHODOLOGY

Missing data and multiple imputation in clinical epidemiological research

This article was published in the following Dove Press journal:
Clinical Epidemiology
15 March 2017
Number of times this article has been viewed

Alma B Pedersen[1]
Ellen M Mikkelsen[1]
Deirdre Cronin-Fenton[1]
Nickolaj R Kristensen[1]
Tra My Pham[2]
Lars Pedersen[1]

Abstract: Missing data are ubiquitous in clinical epidemiological research. Individuals with missing data may differ from those with no missing data in terms of the outcome of interest and prognosis in general. Missing data are often categorized into the following three types: missing completely at random (MCAR), missing at random (MAR), and missing not at random (MNAR). In clinical epidemiological research, missing data are seldom MCAR. Missing data can constitute considerable challenges in the analyses and interpretation of results and can potentially weaken the validity of results and conclusions. A number of methods have been developed for dealing

Consider your research = digital enhancements needed?



Research Article

Immunotherapy

For reprint orders, please contact: reprints@futuremedicine.com

Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of *BRAF*-mutant advanced melanoma: a matching-adjusted indirect comparison

Michael B Atkins*[,1], Ahmad Tarhini[‡,2], Michael Rael[‡,3], Komal Gupte-Singh[4], Elliott O'Brien[3], Corey Ritchings[4], Sumati Rao[4] & David F McDermott[5]

[1]Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
[2]Center for Immuno-Oncology Research, Cleveland Clinic, Cleveland, OH 44106, USA
[3]Evidera, Inc., San Francisco, CA 94111, USA



Methodology

Future ONCOLOGY

For reprint orders, please contact: reprints@futuremedicine.com

I-O Optimise: a novel multinational real-world research platform in thoracic malignancies

Simon Ekman*[,‡,1,2], Frank Griesinger[‡,3], Paul Baas[‡,4], David Chao[‡,5], Christos Chouaid[‡,6], John C O'Donnell[7], John R Penrod[7], Melinda Daumont[8], Laure Lacoin[8], Alexia McKenney[9], Masha Khovratovich[9], Robin EJ Munro[9], Isabelle Durand-Zaleski[‡,10] & Søren Paaske Johnsen[‡,11]

[1]Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
[2]Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
[3]Department of Haematology & Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany
[4]Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
[5]Department of Oncology, Royal Free Hospital, London, UK
[6]Pneumology Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France
[7]Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA
[8]Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Braine-l'Alleud, Belgium



Consider your research = digital enhancements needed?



Clinical Epidemiology

Dovepress

open access to scientific and medical research

Open Access Full Text Article

METHODOLOGY

Danish Prostate Cancer Registry – methodology and early results from a novel national database

This article was published in the following Dove Press journal:
Clinical Epidemiology
27 September 2016
Number of times this article has been viewed

JT Helgstrand[1]

Background: Systematized Nomenclature of Medicine (SNOMED) codes are computer-



Rheumatol Ther (2018) 5:99–122
https://doi.org/10.1007/s40744-018-0106-6

CrossMark

ORIGINAL RESEARCH

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Peter Nash · Iain B. McInnes · Philip J. Mease · Howard Thom · Matthias Hunger · Andreas Karabis · Kunal Gandhi · Shephard Mpofu · Steffen M. Jugl



Consider your reach = open access, social media etc?

Thank you